GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » Forward Rate of Return (Yacktman) %

TYRA (Tyra Biosciences) Forward Rate of Return (Yacktman) % : 0.00% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Tyra Biosciences's forward rate of return for was 0.00%.

The historical rank and industry rank for Tyra Biosciences's Forward Rate of Return (Yacktman) % or its related term are showing as below:

TYRA's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 3.265
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Tyra Biosciences Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Tyra Biosciences's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences Forward Rate of Return (Yacktman) % Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial - - - - -

Tyra Biosciences Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tyra Biosciences's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Tyra Biosciences's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyra Biosciences's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Forward Rate of Return (Yacktman) % falls into.


;
;

Tyra Biosciences Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Tyra Biosciences's Forward Rate of Return of Mar. 2025 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/9.3+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tyra Biosciences  (NAS:TYRA) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Tyra Biosciences Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyra Biosciences Business Description

Industry
Traded in Other Exchanges
N/A
Address
2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Executives
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alan Fuhrman officer: Chief Financial Officer C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Todd Harris director, officer: Chief Executive Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Daniel Bensen officer: Chief Operating Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ali D. Fawaz officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alta Partners Nextgen Fund Ii, L.p. 10 percent owner 4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert J More director, 10 percent owner 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Melissa Mccracken director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008